CiRA, Takeda & T-CiRA
Less than five years ago the Center for iPS Cell Research and Application (CiRA)1 at Kyoto University and Takeda Pharmaceutical (TAK)2 established a research program. Today, Takeda and CiRA announced that induced pluripotent stem cell-derived chimeric antigen receptor (CAR) T-cell therapy (iCART . . .
This content is for paid subscribers.
Today’s Highlights July 17, 2019